Singapore markets close in 7 hours 1 minute
Straits Times Index
3,142.38+3.57(+0.11%)Nikkei
27,749.58-220.64(-0.79%)Hang Seng
25,254.30+167.87(+0.67%)FTSE 100
6,996.08-29.35(-0.42%)BTC-USD
39,804.39+2,894.91(+7.84%)CMC Crypto 200
933.86+57.62(+6.58%)
VCPlus Limited (43E.SI)
SES - SES Delayed Price. Currency in SGD
Add to watchlist
0.02100.0000 (0.00%)
As of 4:56PM SGT. Market open.
| Previous close | 0.0210 |
| Open | 0.0210 |
| Bid | 0.0210 x 0 |
| Ask | 0.0210 x 0 |
| Day's range | 0.0210 - 0.0210 |
| 52-week range | 0.0060 - 0.0360 |
| Volume | 1,620,200 |
| Avg. volume | 17,552,564 |
| Market cap | 91.698M |
| Beta (5Y monthly) | 2.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0040 |
| Earnings date | 26 Feb 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).
© 2021 Verizon Media. All rights reserved.
